Sylvamo (SLVM) delivered the second-half earnings inflection it had promised, alongside a strategic reset. Adjusted earnings from continuing operations were $1.33 per share, 27.9% above the $1.04 consensus, though still down 7.6% from a year ago. Revenue was $645.0 million against a $815.0 million consensus, a 20.9% miss, with sales down 23.8% year over year. Those revenue comparisons need context. Europe is now reported as discontinued operations and contributed $178 million in the quarter, so the consensus and year-ago figures appear to reflect the old structure. On the recast basis in the release, continuing net sales slipped only modestly, from $662 million to $645 million. The central tension is that Sylvamo produced a credible quarter and a cleaner story, while the call trimmed several pieces of the 2027 earnings bridge investors had been counting on.

The quality of the beat deserves scrutiny. GAAP continuing EPS of $2.13 was inflated by $0.83 of net special-item benefits, mainly a $36 million tax benefit tied to the European subsidiaries. The adjusted $1.33 is the better gauge. The sequential jump from $0.35 in the recast second quarter was largely mechanical: planned maintenance outage costs fell $38 million, while price and mix added a more durable $25 million as paper increases were mostly implemented. Adjusted EBITDA reached $128 million at a 20% margin, versus $66 million and 11% in the recast second quarter. Against the prior year, however, it was $158 million at a 24% margin. Latin America's margin was 18% versus 26% a year ago. Free cash flow of $16 million compared with $64 million last year, as a North America inventory build absorbed about $42 million of working capital. The consolidated net loss of $199 million was driven by a $342 million noncash Europe impairment. Total debt has also risen since December while equity fell to $740 million.

The call explained why the improvement is real but less complete than hoped. Input and transportation costs were $6 million unfavorable sequentially and are expected to worsen by another $6 million in the fourth quarter. That brings roughly $50 million of 2026 inflation versus 2025, which management expects to carry into 2027. This reverses the second-quarter view that second-half input costs would be favorable. Demand was flat. North America volume is guided flat for 2027 against industry demand down about 2%, and imports are rising in both regions. The most consequential revision concerned the one-time Eastover costs. Only about $25 million of the roughly $65 million incurred in 2026 is now expected not to repeat in 2027. That is a meaningful retreat from earlier framing that these costs would largely disappear.

The Sumter decision captures the trade-off. Management will add a fourth sheeter rather than replace one, lifting cutsize converting capacity by about 200,000 tons to 500,000 tons. The company says the project still carries an IRR above 30%. But startup slips to early third-quarter 2027 from the fourth-quarter 2026 ramp described earlier. The change adds roughly $25 million of 2027 capex and leaves about $20 million of outsourced converting costs in place for much of next year. On the positive side:

• Eastover machine optimization is about 60% complete and on budget.
• Colombia's removal of antidumping duties reopens a former market for Brazilian uncoated freesheet.
• Lean projects have identified about $15 million in annualized savings.
• $6 million to $7 million per quarter of stranded corporate costs could be addressed after the Europe deal closes.

The Europe exit is the strategic headline. The put option with Midas Atlantic Partners would remove a chronic drag. Sylvamo would retain a 20% non-dilutable interest in future distributions or sale proceeds, with closing targeted by the end of the first quarter of 2027. The poison pill is also being allowed to expire. Offsetting that, the investor day promised for 2026 has been pushed to mid-2027, and post-Europe long-term targets have not been formally updated.

The market had been pricing in skepticism. Shares were $33.07 heading into the report, 15.8% below the open after the August release and 16.9% under the 200-day moving average. The stock had set a 52-week low of $30.40 on October 12 and entered earnings only 8.8% above that level. Investor sentiment remained negative but improved modestly, from -0.32 to -0.25. That suggests expectations were low rather than recovering.

The bottom line is that Sylvamo cleared a low bar with a genuine price-driven rebound and a decisive Europe exit, leaving a simpler, more focused company. Bears still have legitimate ammunition. Persistent cost inflation, flat volumes, a delayed sheeter and a smaller-than-expected 2027 cost rollover all mean the path back to prior-year profitability looks longer than the third-quarter beat alone implies.